Royalty Pharma plc last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $690.1 million (+13.3% year over year) and diluted EPS of $0.32. It usually reports 35–42 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 10, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Feb 11, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–42 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
690
+13.3%
|
145
-49.1%
|
0.32
-51.5%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
674
+16.5%
|
18
-44.4%
|
0.04
-42.9%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
631
+11.0%
|
295
+23.1%
|
0.67
+21.8%
|
|
Feb 11, 2026
42 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
622
+4.8%
|
215
+3.4%
|
0.39
+9.2%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
609
+7.9%
|
284
-47.8%
|
0.66
-45.5%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
579
+7.7%
|
32
-68.5%
|
0.07
-69.6%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
568
+0.0%
|
239
+4909.4%
|
0.55
+5400.0%
|
|
Jan 10, 2025
10 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
594
-0.4%
|
208
-57.9%
|
0.35
-57.3%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RPRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1802768
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.